NASDAQ · GPCR

Structure Therapeutics Inc.. American

$48.69 -$0.43 (-0.88%) 1D After hours

Key Metrics

$3.49B
Market cap
P/E · TTM
Revenue · TTM
−$170.34M
Net income
EPS · TTM $-0.99
Dividend yield
Free cash flow −$159.22M
Beta · 1Y 1.04
EBITDA · TTM −$168.10M
Gross margin

The Story So Far

LAST 6 MONTHS PRIMARY SOURCES ONLY
  • Jul 16
    Money rotated out of high-beta cohorts market-wide.

    High-beta names lagged the blue-chips by 20.3 points over ten sessions around this date. Stocks in that cohort weren't falling alone — they fell together.

    RECEIPT: ROTATION GAUGE, LIVE
  • May 19
    From its Feb 2 high, the share price fell 60%.

    Peak close $89.84 on Feb 2; trough close $35.88 on May 19. The drawdown is the fact — the chapters around it are the context.

    RECEIPT: PRICE SERIES, PEAK-TO-TROUGH -60%
  • Mar 31
    The stock moved +9.7% in a single session.

    Sessions this size usually pair with a chapter above or below — a filing, a headline, or the whole cohort moving together.

    RECEIPT: DAILY BAR, Mar 31
  • Feb 5
    The stock moved -9.9% in a single session.

    Sessions this size usually pair with a chapter above or below — a filing, a headline, or the whole cohort moving together.

    RECEIPT: DAILY BAR, Feb 5

The story updates itself as events post · The wolf reports; you decide

Snapshot

Market cap$3.49B
Enterprise value
Shares outstanding71.1M
52-wk range$15.80 – $94.90
Avg volume · 20D824.9K
Net cash
Book value / share$8.41
IndustryPharmaceutical Preparations
ExchangeNASDAQ
About Structure Therapeutics Inc.. American
IPO dateFeb 3, 2023
Employees233

Structure Therapeutics Inc is a clinical-stage biopharmaceutical company developing novel oral small-molecule therapeutics to treat a wide range of chronic diseases with unmet medical needs.

Wolf Grade COMING SOON

The wolf is in training. Composite grades vs sector — profitability, health, value, momentum — arrive with the percentile engine. Methodology will be public.

Valuation

P/E
P/S
P/FCF
EV/EBITDA
EV/Sales
Graham №

Profitability

Gross
Operating
Net
FCF
ROE / ROIC -14.7% · 1,492.9%

Financial Health

Current ratio26.16
Quick ratio
Debt / equity
Debt / EBITDA
Net cash
Working capital$1.43B

Cash Flow · TTM

Operating CF −$154.74M
Capex −$4.48M
Free cash flow −$159.22M
Buybacks
Dividends paid
Shareholder yield

Piotroski F-Score

2 / 9
Weak fundamentals · 2 of 9 signals passing

Altman Z-Score

Insufficient balance-sheet inputs

Graham Number vs Price

Requires positive earnings and book value
Fundamentals through 2026-03-31 · computed by TickerWolf from SEC filings